Advertisement

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Published:October 08, 2019DOI:https://doi.org/10.1016/j.ygyno.2019.09.008

      Highlights

      • We report a cohort of 115 ovarian cancer patients treated with olaparib.
      • Median PFS was 12.7 months and median OS was 35.4 months, comparable to Study 19.
      • PFI ≥ 12 months, CR and normalized CA-125 are associated with prolonged PFS and OS

      Abstract

      Objective

      To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in daily practice.

      Methods

      Multicenter (8 hospitals) European retrospective study of relapsing EOC patients having germline or somatic mutations of BRCA1/BRCA2 genes and treated with olaparib as maintenance therapy after platinum-based chemotherapy.

      Results

      One hundred and fifteen patients were included. Median age was 54 years. There were 90 BRCA1 carriers, 24 BRCA2 carriers and one patient had germline mutation of BRCA1 and BRCA2. Six patients had somatic mutations (all BRCA1) and 109 had germline mutations. Ninety percent had serous carcinomas and were platinum-sensitive. Following ultimate platinum-based chemotherapy, 69% of the patients had normalization of CA-125 levels and 87% had RECIST objective responses, either partial (53%) or complete (34%). After a median follow-up of 21 months, median PFS was 12.7 months and median OS was 35.4 months. In multivariate analysis, factors associated with prolonged PFS under olaparib were: platinum-free interval (PFI) ≥ 12 months, RECIST complete response (CR) or partial response (PR) and normalization of CA-125 upon ultimate platinum-based chemotherapy. Factors associated with prolonged OS were PFI ≥ 12 months, CR and normalization of CA-125.

      Conclusions

      Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.L.
        • Torre L.A.
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J. Clin. 2018; 68: 394-424
        • Kurman R.J.
        • Shih Ie M.
        Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm.
        Hum. Pathol. 2011; 42: 918-931
        • Norquist B.M.
        • Brady M.F.
        • Harrell M.I.
        • Walsh T.
        • Lee M.K.
        • Gulsuner S.
        • et al.
        Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology/gynecologic oncology group study.
        Clin. Cancer Res. 2018; 24: 777-783
        • Alsop K.
        • Fereday S.
        • Meldrum C.
        • deFazio A.
        • Emmanuel C.
        • George J.
        • et al.
        BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group.
        J. Clin. Oncol. 2012; 30: 2654-2663
        • Cancer Genome Atlas Research N
        Integrated genomic analyses of ovarian carcinoma.
        Nature. 2011; 474: 609-615
        • Bolton K.L.
        • Chenevix-Trench G.
        • Goh C.
        • Sadetzki S.
        • Ramus S.J.
        • Karlan B.Y.
        • et al.
        Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
        JAMA. 2012; 307: 382-390
        • Bryant H.E.
        • Schultz N.
        • Thomas H.D.
        • Parker K.M.
        • Flower D.
        • Lopez E.
        • et al.
        Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
        Nature. 2005; 434: 913-917
        • Farmer H.
        • McCabe N.
        • Lord C.J.
        • Tutt A.N.
        • Johnson D.A.
        • Richardson T.B.
        • et al.
        Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
        Nature. 2005; 434: 917-921
        • Gelmon K.A.
        • Tischkowitz M.
        • Mackay H.
        • Swenerton K.
        • Robidoux A.
        • Tonkin K.
        • et al.
        Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
        Lancet Oncol. 2011; 12: 852-861
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
        N. Engl. J. Med. 2012; 366: 1382-1392
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 852-861
        • Pujade-Lauraine E.
        • Ledermann J.A.
        • Selle F.
        • Gebski V.
        • Penson R.T.
        • Oza A.M.
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1274-1284
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • Oza A.M.
        • Mahner S.
        • Redondo A.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N. Engl. J. Med. 2016; 375: 2154-2164
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • Aghajanian C.
        • Oaknin A.
        • Dean A.
        • et al.
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • Khozin S.
        • Blumenthal G.M.
        • Pazdur R.
        Real-world data for clinical evidence generation in oncology.
        J. Natl. Cancer Inst. 2017; 109
        • Gronlund B.
        • Hogdall C.
        • Hilden J.
        • Engelholm S.A.
        • Hogdall E.V.
        • Hansen H.H.
        Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?.
        J. Clin. Oncol. 2004; 22: 4051-4058
        • Colombo P.E.
        • Fabbro M.
        • Theillet C.
        • Bibeau F.
        • Rouanet P.
        • Ray-Coquard I.
        Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.
        Crit Rev Oncol Hematol. 2014; 89: 207-216
        • Tomao F.
        • D’Incalci M.
        • Biagioli E.
        • Peccatori F.A.
        • Colombo N.
        Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?.
        Cancer. 2017; 123: 3450-3459
        • Colombo N.
        • Sessa C.
        • du Bois A.
        • Ledermann J.
        • McCluggage W.G.
        • McNeish I.
        • et al.
        ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
        Ann Oncol. 2019 May 1; 30: 672-705
        • Friedlander M.
        • Matulonis U.
        • Gourley C.
        • du Bois A.
        • Vergote I.
        • Rustin G.
        • et al.
        Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
        Br. J. Cancer. 2018; 119: 1075-1085
        • Lheureux S.
        • Lai Z.
        • Dougherty B.A.
        • Runswick S.
        • Hodgson D.R.
        • Timms K.M.
        • et al.
        Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization.
        Clin. Cancer Res. 2017; 23: 4086-4094
        • Dougherty B.A.
        • Lai Z.
        • Hodgson D.R.
        • Orr M.C.M.
        • Hawryluk M.
        • Sun J.
        • et al.
        Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
        Oncotarget. 2017; 8: 43653-43661
        • Liu J.F.
        • Barry W.T.
        • Birrer M.
        • Lee J.M.
        • Buckanovich R.J.
        • Fleming G.F.
        • et al.
        Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
        Ann. Oncol. 2019 May; 25: 740-750
        • McAlpine J.N.
        • Porter H.
        • Kobel M.
        • Nelson B.H.
        • Prentice L.M.
        • Kalloger S.E.
        • et al.
        BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
        Mod. Pathol. 2012; 25: 740-750
        • Ovarian Tumor Tissue Analysis C
        • Goode E.L.
        • Block M.S.
        • Kalli K.R.
        • Vierkant R.A.
        • Chen W.
        • et al.
        Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer.
        JAMA Oncol. 2017; 3e173290
        • Strickland K.C.
        • Howitt B.E.
        • Shukla S.A.
        • Rodig S.
        • Ritterhouse L.L.
        • Liu J.F.
        • et al.
        Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
        Oncotarget. 2016; 7: 13587-13598
        • Ding L.
        • Kim H.J.
        • Wang Q.
        • Kearns M.
        • Jiang T.
        • Ohlson C.E.
        • et al.
        PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer.
        Cell Rep. 2018; 25: 2972-80 e5
        • Labidi-Galy S.I.
        • Olivier T.
        • Rodrigues M.
        • Ferraioli D.
        • Derbel O.
        • Bodmer A.
        • et al.
        Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.
        Clin Cancer Res. 2018 Jan 15; 24: 326-333
        • Drost R.
        • Dhillon K.K.
        • van der Gulden H.
        • van der Heijden I.
        • Brandsma I.
        • Cruz C.
        • et al.
        BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
        J. Clin. Invest. 2016; 126: 2903-2918
        • Friedlaender A.
        • Vuilleumier A.
        • Viassolo V.
        • Ayme A.
        • De Talhouet S.
        • Combes J.D.
        • et al.
        BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
        Breast Cancer Res. Treat. 2019 Apr; 174: 775-783